Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-009752
Filing Date
2020-03-10
Accepted
2020-03-10 16:18:21
Documents
49
Period of Report
2020-01-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-10q_20200131.htm 10-Q 1486662
2 EX-31.1 kalv-ex311_6.htm EX-31.1 21425
3 EX-31.2 kalv-ex312_7.htm EX-31.2 18830
4 EX-32.1 kalv-ex321_8.htm EX-32.1 8642
  Complete submission text file 0001564590-20-009752.txt   4552834

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT kalv-20200131.xml EX-101.INS 874131
6 XBRL TAXONOMY EXTENSION SCHEMA kalv-20200131.xsd EX-101.SCH 34878
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kalv-20200131_cal.xml EX-101.CAL 58611
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kalv-20200131_def.xml EX-101.DEF 74857
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20200131_lab.xml EX-101.LAB 281094
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20200131_pre.xml EX-101.PRE 193948
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 20701746
SIC: 2834 Pharmaceutical Preparations